<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/299DAA83-B7CA-402C-B5C2-60ACF59C5720"><gtr:id>299DAA83-B7CA-402C-B5C2-60ACF59C5720</gtr:id><gtr:name>Glythera Limited</gtr:name><gtr:address><gtr:line1>INEX HERSCHEL ANNEX , KINGS ROAD</gtr:line1><gtr:city>NEWCASTLE UPON TYNE</gtr:city><gtr:postCode>NE1 7RU</gtr:postCode><gtr:region>North East</gtr:region></gtr:address><gtr:typeInd>P</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/299DAA83-B7CA-402C-B5C2-60ACF59C5720" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="gtr:organisationParticipantRole"><gtr:id>299DAA83-B7CA-402C-B5C2-60ACF59C5720</gtr:id><gtr:name>Glythera Limited</gtr:name><gtr:address><gtr:line1>INEX HERSCHEL ANNEX , KINGS ROAD</gtr:line1><gtr:city>NEWCASTLE UPON TYNE</gtr:city><gtr:postCode>NE1 7RU</gtr:postCode><gtr:region>North East</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_PARTICIPANT</gtr:name></gtr:role><gtr:role><gtr:name>PARTICIPANT</gtr:name></gtr:role></gtr:roles><gtr:offerGrant>56318.0</gtr:offerGrant><gtr:projectCost>75090.0</gtr:projectCost></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/A40B05D5-27FA-4B57-84A3-3A31B4A08087" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="gtr:organisationParticipantRole"><gtr:id>A40B05D5-27FA-4B57-84A3-3A31B4A08087</gtr:id><gtr:name>Centre for Process Innovation Limited</gtr:name><gtr:address><gtr:line1>WILTON CENTRE , WILTON,</gtr:line1><gtr:city>REDCAR</gtr:city><gtr:postCode>TS10 4RF</gtr:postCode><gtr:region>North East</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>PARTICIPANT</gtr:name></gtr:role></gtr:roles><gtr:offerGrant>15218.0</gtr:offerGrant><gtr:projectCost>15218.0</gtr:projectCost></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D3810AAC-4354-409E-B932-50420433B82D" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="gtr:organisationParticipantRole"><gtr:id>D3810AAC-4354-409E-B932-50420433B82D</gtr:id><gtr:name>Glycoselect (UK) Limited</gtr:name><gtr:address><gtr:line1>ROSSLYN HOUSE HOLMES CHAPEL ROAD , SOMERFORD</gtr:line1><gtr:city>CONGLETON</gtr:city><gtr:postCode>CW12 4SP</gtr:postCode><gtr:region>North West</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>PARTICIPANT</gtr:name></gtr:role></gtr:roles><gtr:offerGrant>103831.0</gtr:offerGrant><gtr:projectCost>138442.0</gtr:projectCost></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/7B002DC8-A74F-46DA-80D1-647A56A8345A"><gtr:id>7B002DC8-A74F-46DA-80D1-647A56A8345A</gtr:id><gtr:firstName>David</gtr:firstName><gtr:surname>Simpson</gtr:surname><gtr:roles><gtr:role><gtr:name>PROJECT_MANAGER</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=131915"><gtr:id>4EE5F138-5E4E-4A75-9539-F82434595EAC</gtr:id><gtr:title>Improving the therapeutic window of glycosylated drug classes and the development of a novel, rapid, high throughput analytical methodology to streamline the drug development pathway.</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Feasibility Studies</gtr:grantCategory><gtr:grantReference>131915</gtr:grantReference><gtr:abstractText>Development of biotherapeutics is risky and expensive with current timelines from bench to bedside being estimated at 7-10 years at a cost of $2.8bn. This project exploits Glythera?s technology which can stabilise glycosylation profiles to increase bioavailability and the therapeutic window to enhance the efficacy of the drug but also patient care through the reduction in dosing cycles. GlycoSelect will develop a highly specific lectin to Glythera?s technology as a supporting and orthogonal approach to analytical development and characterisation. Since this rapid methodology can be deployed during any point in the discovery through to the clinical development programme this would support and significant de-risk drug development efforts. Both companies will demonstrate the value of their combined technologies through the further development of improved drug classes and comparison to known analytical methods underpinning their importance in drug development.</gtr:abstractText><gtr:fund><gtr:end>2016-07-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/E18E2F0F-AC7D-4E02-9559-669F7C8FEC74"><gtr:id>E18E2F0F-AC7D-4E02-9559-669F7C8FEC74</gtr:id><gtr:name>Innovate UK</gtr:name></gtr:funder><gtr:start>2015-08-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>175367</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications/><gtr:identifiers><gtr:identifier type="RCUK">131915</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects/><gtr:researchTopics><gtr:researchTopic><gtr:id>D05BC2E0-0345-4A3F-8C3F-775BC42A0819</gtr:id><gtr:text>Unclassified</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>